公开(公告)号：US20210030888A1

公开(公告)日：2021-02-04

申请号：US16978539

申请日：2019-03-06

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Esther Cornelia Wilhelmina BREIJ ,  David SATIJN ,  Sandra VERPLOEGEN ,  Jantine BAKEMA ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Andreas LINGNAU

IPC: A61K47/68 ,  C07K16/36 ,  A61K9/00 ,  A61P35/00

Abstract: The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer).

公开(公告)号：US20220273809A1

公开(公告)日：2022-09-01

申请号：US17628382

申请日：2020-07-17

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Nora PENCHEVA ,  Esther Cornelia Wilhelmina BREIJ ,  Julia BOSHUIZEN ,  Daniel Simon PEEPER ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Patricia Garrido CASTRO

IPC: A61K47/68 ,  A61P35/00 ,  A61K47/02

Abstract: The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.

公开(公告)号：US20230295335A1

公开(公告)日：2023-09-21

申请号：US18184120

申请日：2023-03-15

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Andreea IOAN ,  Esther Cornelia Wilhelmina BREIJ ,  Lars GUELEN ,  David P.E. SATIJN ,  Ugur SAHIN ,  Alexander MUIK ,  Kristina SCHÖDEL ,  Sina FELLERMEIER-KOPF ,  Bart-Jan DE KREUK ,  Richard HIBBERT ,  Janine SCHUURMAN ,  Aran Frank LABRIJN

IPC: C07K16/30 ,  C07K16/28

CPC classification number: C07K16/30 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/92

Abstract: The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.

公开(公告)号：US20150004177A1

公开(公告)日：2015-01-01

申请号：US14317600

申请日：2014-06-27

Applicant: GENMAB A/S

Inventor： Edward Norbert VAN DEN BRINK ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Aran Frank LABRIJN ,  Frank Everhardus Martinus REBERS ,  Esther Cornelia Wilhelmina BREIJ

IPC: C07K16/28

CPC classification number: C07K16/283 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Abstract translation: 公开了与人CD32b和相关的基于抗体的组合物和分子结合的分离的单克隆抗体。 还公开了包含抗体的药物组合物，以及使用抗体的治疗和诊断方法。

公开(公告)号：US20240327544A1

公开(公告)日：2024-10-03

申请号：US18579086

申请日：2022-07-13

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Sina FELLERMEIER-KOPF ,  Yali FU ,  Homer ADAMS, III ,  Gaurav BAJAJ ,  Brandon HIGGS ,  Mark FERESHTEH ,  Vanessa SPIRES ,  Jordan BLUM ,  Patricia GARRIDO CASTRO ,  Michelle NIEWOOD ,  Friederike GIESEKE ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Ivan KUZMANOV ,  Esther Cornelia Wilhelmina BREIJ ,  Lars GUELEN ,  Jost NEIJSSEN ,  Bart-Jan DE KREUK ,  Richard HIBBERT ,  Janine SCHUURMAN ,  Aran Frank LABRIJN

IPC: C07K16/46 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/76

Abstract: The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20230365693A1

公开(公告)日：2023-11-16

申请号：US18315686

申请日：2023-05-11

Applicant: BioNTech SE ,  Genmab A/S

Inventor： Ugur SAHIN ,  Sina FELLERMEIER-KOPF ,  Friederike GIESEKE ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Alexander MUIK ,  Ivan KUZMANOV ,  Esther Cornelia Wilhelmina BREIJ ,  Patricia GARRIDO CASTRO ,  Jordan BLUM ,  Lars GUELEN ,  Joost NEIJSSEN ,  Bart-Jan DE KREUK ,  Richard HIBBERT ,  Janine SCHUURMAN ,  Aran Frank LABRIJN

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.